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ABSTRACT
RACHEL LEIGH JENKINS: Targeting G-Quadruplexes within the ADAM-15
Promoter: A Novel Therapeutic Approach for Breast Cancer
(Under the direction of Dr. Tracy A. Brooks)

ADAM-15 is a protein that is up-regulated in many diseases, particularly breast
cancer; its over-expression is correlated with more aggressive and invasive phenotypes.
The critical core promoter region of ADAM-15 is capable of forming a secondary DNA
structure known as a G-quadruplex. The stabilization of this G-quadruplex has the
potential to decrease the transcription of the over-expressed ADAM-15 protein. Six
hundred forty compounds were screened for their ability to cause a shift in the melting
temperature of an ADAM-15 oligonucleotide using FRET melt. Two compounds, NSC
146771 and NSC 260594, produced a significant shift in the melting temperature; further
experimentation, such as circular dichroism, cytotoxicity MTS assays, and RT-qPCR,
was performed to confirm the ability of these small molecules to stabilize the Gquadruplexes within the ADAM-15 promoter. Neither compound showed cytotoxicity,
and NSC 260594 showed an increased capacity for reducing the transcription of ADAM15. Further pharmacokinetic and pharmacodynamic experimentation needs to be
completed, but NSC 260594 shows potential to significantly decrease ADAM-15
expression and therefore improve the prognosis of breast cancer patients.
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INTRODUCTION
ADAM (A Disintegrin and Metalloproteinase) proteins are membrane-bound cell
surface glycoproteins that have a variety of functions in cells, including growth,
differentiation, and motility (Lendeckel, 2005). ADAM's basic structure is comprised of
modular metalloproteinase motifs, an integrin-binding domain (disintegrin), and a
cysteine-rich epidermal growth factor-like domain in the extracellular region (Kuefer,
2006). ADAMs include more than 30 different family members, and these members'
functions encompass neurogenesis and angiogenesis, signaling through the epidermal
growth factor receptor (EGFR), activating the Notch receptor, and shedding various
membrane-bound proteins such as cytokines, growth factors, and adhesion molecules
(Lendeckel, 2005; Maretzky, 2009). Members of the ADAM family are normally
expressed in early embryonic development, where they play a role in contributing to the
homeostasis of the extracellular matrix, organogenesis, transduction of signals, tissue
remodeling, adhesion, inflammation, and cell migration (Brown, 2013; Lendeckel, 2005).
However, some ADAM family members can become abnormally expressed in several
types of diseases, including inflammatory disorders, atherosclerosis and various cancers
(Lu, 2010).
The focus of this study is on human ADAM-15, which is known to be upregulated in many adenocarcinomas, specifically metastatic prostate cancer, breast
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cancer, and melanoma (Maretzky, 2009; Kuefer, 2006). ADAM-15 is located on
chromosome 1 at position 1q21.3, as shown in Figure 1 (Lu, 2010). The gene encoding
ADAM-15 contains 23 exons and 22 introns; its extracellular domains include a prodomain, metalloproteinase domain, disintegrin-like domain, cysteine-rich domain, and
EGF-like domain, demonstrated in Figure 2 (Lu, 2010). The cytosolic C-terminal tail of
ADAM-15 contains Src homology 2 and 3 recognition sequences, which can bind to
adapter proteins such as Grb2, SH3PX1, and endophilin I; thus, this cytoplasmic portion
could play a role in signal transduction and protein localization (Najy, 2008). The
disintegrin domain of ADAM-15 detaches cells from the extracellular matrix, and the
metalloproteinase domain degrades cells from the extracellular matrix (Kuefer, 2006).
Notably, ADAM-15 is the only ADAM family member that has the integrin binding
motif Arg-Gly-Asp (RGD) in its disintegrin-like domain, which is analogous to a
sequence found in snake venom disintegrins (Lu, 2010; Kuefer, 2006). These
disintegrins are known to be potent inhibitors of various integrins; therefore, this domain
is thought to interfere with cell-cell and cell-matrix interactions (Lu, 2010). In addition
to the degradation of collagens I and IV in the extracellular matrix, the metalloproteinase
domain of ADAM-15 also plays a role in the ectodomain shedding of growth factors,
growth factor receptors, and adhesion molecules (Najy, 2008). The shedding of these
molecules can render a tumor cell resistant to growth inhibitory or differentiating signals,
which can contribute to the progression of metastasis (Lendeckel, 2005).
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Figure 1. Location of the ADAM-15 gene on chromosome 1.
From Lu D, Scully M, Kakkar V, Lu X. ADAM-15 disintegrin-like domain structure and
function. Toxins. 2010 October 19; 2(10): 2411-2427.

Figure 2. Domain structures of ADAMs compared to snake venom metalloproteinases (SVMP).
From Lu D, Scully M, Kakkar V, Lu X. ADAM-15 disintegrin-like domain structure and
function. Toxins. 2010 October 19; 2(10): 2411-2427.
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One of ADAM-15's most significant activities in its role in breast cancer is its
promotion of the extracellular shedding of epidermal cadherin (E-cadherin), a type I
transmembrane glycoprotein (Brown, 2013; Najy, 2008). E-cadherin is important in cellcell interactions, and its role is well established in embryonic development, organ
morphogenesis, tissue integrity, and wound healing (Najy, 2008). However, the
disruption of E-cadherin by proteolytic cleavage leads to the loss of cell-cell integrity,
promoting cell migration and invasion (Najy, 2008). Correspondingly, the soluble Ecadherin fragment (sE-cad) produced by this ectodomain shedding is increased in the
serum and urine of patients with breast, prostate, ovarian, gastric, melanoma, and bladder
cancers and is a marker of poor prognosis (Najy, 2008). Interestingly, this sE-cad
fragment binds to and stabilizes the ErbB receptor HER2 and HER3 heterodimerization,
leading to Erk-dependent signaling, which causes activation, increased motility, and
proliferation in these cancer cells (Najy, 2008; Brown, 2013).
Because of these activities, ADAM-15 is thought to play a significant role in the
metastasis of cancers. In fact, higher levels of amplification of the region of chromosome
1 in which ADAM-15 is located are associated with more advanced metastatic cancers, as
opposed to lower levels of amplification in primary diseases (Kuefer, 2006). Therefore,
there is an increased expression of ADAM-15 as the cancer progresses from low-grade to
more advanced and metastatic grades (Kuefer, 2006). ADAM-15 is significantly upregulated during breast cancer progression, and increased sE-cad levels are also
correlated with advanced breast cancer (Najy, 2008). Additionally, the HER2 receptor, to
which the sE-cad produced by ADAM-15's activity binds, is over-expressed in 20 - 30%
of breast cancers and is also a marker of poor prognosis (Najy, 2008). It has been
4

demonstrated that ADAM-15 and HER2 are up-regulated simultaneously during breast
cancer progression, and that targeted down-regulation of both of ADAM-15 and HER2
function to synergistically kill breast cancer cells (Najy, 2008; Brown, 2013). However,
to date there are no therapeutic options for decreasing ADAM-15 function or expression
(Brown, 2013). Thus, the focus of this study was to elucidate novel therapeutic strategies
for targeting ADAM-15 in breast cancer cells.
The critical core promoter of ADAM-15 contains a unique string of guanine-rich
DNA that consists of seven neighboring runs of three or more consecutive guanines.
Under superhelical strain, this region can relax from the double-helical form of DNA and
can form an intrastrand secondary-DNA structure known as a G-quadruplex (Brown,
2013). G-quadruplexes were first described by Davies and co-workers in 1962, and since
have been found in telomeres, gene promoters, ribosomal DNA, mini-satellites, and the
immunoglobulin heavy chain switch region, demonstrating their widely varied biological
roles. These structures form through an association of four guanines into a cyclic
Hoogsteen hydrogen bonding motif, where each guanine nucleotide base forms two
hydrogen bonds with its neighbors; this basic structure is known as a G-quartet (Ou,
2008). Two or more of these G-quartets can then stack on top of each other and are
connected by intervening variable-length sequences that form loops on the exterior of the
core. These loops are analogous to amino acid side chains, and they are the major
elements that define the structural variability in G-quadruplexes (Balasubramanian,
2011). The loops can vary in strand stoichiometry, strand polarity, glycosidic torsion
angle, and in the location in which they link the guanine strands (Ou, 2008). Though Gquadruplexes are widespread, the diversity conferred by the loops suggests that a high
5

level of selectivity could be possible when targeting these structures (Balasubramanian,
2011). It has been shown that many gene promoter G-quadruplex sequences are capable
of forming more than one discrete arrangement and that these arrangements may be in
dynamic equilibrium with each other (Balasubramanian, 2011). The sequence of
contiguous runs of guanines and the major G-quadruplex species formed in the ADAM15 promoter sequence are shown in Figure 3.
The significance of G-quadruplex formation in the ADAM-15 promoter is its
putative ability to control transcription of this gene. G-quadruplexes have been found to
form in the promoters of many other oncogenes, including c-MYC, c-Kit, kRAS, pRb,
Bcl-2, VEGF-A, hTERT, and PDGF-A. Significantly, altered expression of these
oncogenes are recognized as the hallmarks of cancer because they have the capacity for
self-sufficiency of growth signals, insensitivity to anti-growth signals, evasion of
apoptosis, sustained angiogenesis, limitless replicative potential, and tissue invasion and
metastasis (Brooks, 2010). Generally, stabilization of these G-quadruplexes suppresses
the genes' expression; for example, stabilization of the G-quadruplex in the NHE III1
region of the promoter of c-MYC turns down transcriptional activation, down-regulates
mRNA expression, inhibits cell proliferation, and induces delayed apoptosis of
lymphoma cells (Brown, 2011). Likewise, G-quadruplex formation within the ADAM15 promoter affects the rate of transcription and leads to a down-regulation of protein
expression (Brown, 2013).
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A

B
5'-end

5'-mid

3'-mid

3'-end

Figure 3. Guanine sequence and major G-quadruplex species in ADAM-15 promoter sequence.
(A) Contiguous runs of guanine in the 5'-3' ADAM-15 promoter sequence (assigned a through g).
(B) Models of the different G-quadruplex species formed within the ADAM-15 promoter. From
Brown RV, Gaerig VC, Simmons T, Brooks TA. Helping Eve overcome ADAM: G-quadruplexes
in the ADAM-15 promoter as new molecular targets for breast cancer therapeutics. Molecules.
2013 December 5; 18(12): 15019-15034.
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A promising novel anticancer strategy is the stabilization of these G-quadruplexes
within gene promoters by small molecules. Traditional DNA-targeted cancer therapies
such as alkylating agents are dependent on duplex DNA; such therapies can be very nonspecific across the genome and cytotoxic to normal cells (Ou, 2008). However, ideal
ligands that bind quadruplexes should have minimal affinity for duplex DNA, would
have oncogene-selective binding, and should therefore have a lower toxicity to normal
cells (Neidle, 2010). The conformation of G-quadruplexes provides selective recognition
sites for small molecules; variations in the sequences and sizes of the loops in the Gquadruplex are likely potential sites for drug binding (Ou, 2008). There are various
potential binding modes for small molecules to interact with G-quadruplexes, as
illustrated in Figure 4. These binding modes include external stacking on the surface of
the terminal quartet, intercalating between the stacks of the G-quartets, and groove
binding between the loops (Ou, 2008). External stacking and groove binding are thought
to be the major mechanisms in which small molecules interact with G-quadruplexes,
because intercalator binding between quartets requires a very high energy cost to disrupt
the structure of the G-quadruplex (Ou, 2008).
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Figure 4. Small-molecule-G-quadruplex complex binding modes.
From Ou T, Lu Y, Tan J, Huan Z, Wong K, Gu L. G-quadruplexes: targets in anticancer drug
design. ChemMedChem. 2008 May 19; 3(5): 690-713.

Several groups of small molecules have been identified as having the capability to
specifically interact with G-quadruplexes; these compounds include cationic porphyrin
(TMPyP4), acridine (BSU6039), polycyclic acridine (RHPS4), and N,N'-bis-[2-(1piperidino)ethyl]-3,4,9,10-perylenetetracarboxylic diimide (PIPER) (Ou, 2008). Many of
these compounds target a structural feature common to all G-quadruplexes: the large
planar surface of the G-quartet (Balasubramanian, 2011). While the targeting of this
structure does allow differentiation from duplex DNA, this feature by itself is insufficient
for high affinity and unlikely to confer selectivity (Balasubramanian, 2011). For
example, quindoline and berberine are planar aromatic chromophores with one or two
aminoalkyl side chains that down-regulate c-MYC expression in several cancer lines.
However, their derivatives can also act as telomerase inhibitors and inducers of
telomerase damage; therefore, selectivity for one particular type of G-quadruplex is
modest. More selective approaches target the ligand side chain binding pockets in the
grooves and loops of G-quadruplexes (Balasubramanian, 2011). A first-in-class G9

quadruplex-interacting drug, Quarfloxin, progressed to Phase II clinical trials before the
trial was halted due to difficulties with delivery and excessive albumin binding (Brown,
2013). Although bioavailability issues prevented the trial from moving forward,
Quarfloxin's toxicity profile was very low, the compound was well tolerated by patients,
and objective responses were observed during the Phase I clinical trials
(Balasubramanian, 2011). Thus, the future is promising for G-quadruplex-interacting
compounds.
The main objective of this study was to identify small molecules capable of
stabilizing G-quadruplexes in the promoter sequence of ADAM-15, to determine the
effects of these small molecules on the transcriptional control of ADAM-15, and to
discern any cytotoxic effects in vitro. Because of ADAM-15's significance in the
metastasis of breast cancer, and because down-regulation of this gene along with a
HER2/neu-targeted agent has the potential to synergistically kill breast cancer cells, this
study focused on molecules that facilitated the down-regulation ADAM-15 expression in
breast cancer.
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MATERIALS AND METHODS
I. Compound Identification
FRET Melt
Twenty 96-well plates were received from the National Cancer Institute/National
Institute of Health's Developmental Therapeutics Program, several of which were
screened for their ability to stabilize the G-quadruplex within the ADAM-15 promoter.
NCI plates 4721, 4722, 4724, 4725, 4727, 4728, 4729, and 4730 were screened; 80
distinct compounds were in each plate, for a total of 640 compounds examined. A master
mix of 0.4 μM FRET probe (with a G-rich ADAM-15 promoter sequence [5'TTGGGGCCGGGTGGGAGGGGGCGGGCCGGGGCGGGGCC] sandwiched between
a 5'-FAM and a 3'-TAMRA moiety), 10 mM sodium cacodylate buffer, 100 mM lithium
chloride, and double-distilled water (ddH20) was made, based on a final volume of 25
μL/well and 100 wells. This master mix was heated to 95°C for 5 minutes, then allowed
to slowly cool to room temperature. While this was cooling, 2.5 μL of each compound
from the 10x compound stock (100 μM, for a final incubation with DNA at 10 μM) NCI
plates were added to 96-well plates, along with ddH20 or potassium chloride to serve as
negative and positive controls, respectively. Next, 22.5 μL of the room-temperature
master mix was aliquoted to each well. The 96-well plate was then vortexed and
centrifuged. The fluorescence was read on the CFX Connect Real-Time PCR detection
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system in the FAM channel using the FRET MELT program. This program heated the
plate from 25 - 95°C at a rate of 2°C/minute; fluorescence was measured every 1°C.

Circular Dichroism (CD)
Circular dichroism was used to validate the hypothesis that the binding of specific
small molecules to the ADAM-15 promoter and subsequently stabilized the formed Gquadruplex. A master mix of 5 μM ADAM-15 oligonucleotide (or ddH2O), 50 mM trisacetate, 10 mM potassium chloride, and ddH2O was made, with enough to have 300 μL
per spectra. Two hundred seventy microliters of master mix was aliquoted to individual
tubes, and 30 μL compound from 10x compound stock (100 μM) NCI plate was added to
each tube (ddH2O or 10 mM KCl were used to serve as oligonucleotide controls). These
mixtures were heated to 95°C for 10 minutes, then allowed to cool to room temperature
overnight. Matching blanks with all contents but lacking DNA were made to subtract
background data from each sample. The spectra (225-350 nm) and TM (20 - 100°C,
measured at every 10°C after holding for 1 minute at temperature before spectra were
collected) were run on an Olis CD machine, coupled to a Peltier heat block. Data were
converted to a single value decomposition (SVD), which was then used to calculate the
TM using GraphPad Prism®.
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II. Mechanistic Confirmation
Cytotoxicity MTS Assay
A cytotoxicity assay using 3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was used to assess any
cytotoxic effects the identified small molecules had on breast cancer cells (Mosmann,
1983). The breast cancer cell line MCF-7 was grown in Dulbecco's Modified Eagle
Medium (DMEM, purchased from Life Technologies) supplemented with 10% fetal
bovine serum (FBS, Sigma-Aldrich) and 1% penicillin/streptomycin mixture. For the
MTS assay, the cells were trypsinized with 0.5 - 2 mL of TrypLE (Life Technologies) at
37°C for 3 - 5 minutes until they were detached from the flask surface. The cells were
then suspended in 5 mL of media and centrifuged at 4000 rpm for 5 minutes. The
supernatant was discarded and the cells were resuspended in 3 - 5 mL of fresh DMEM.
A mixture of 10 µL of cultured cells and 90 µL of Trypan Blue Solution (0.4%, Life
Technologies), was made; 10 µL of this mixture was placed on a hemocytometer and the
cells were counted to determine the stock concentration. Cells were added to a 96-well
plate, at 1.5 x 104 cells per well for the 24 hour plate and 5 x 103 cells per well for the 72
hour plate; each well was plated with a volume of 90 μL. These cell plates were
incubated overnight. The next day, a 10x drug stock plate was made, with compounds
serially diluted over a 5 - 6 log range, starting from a high dose of 1 mM (for a high dose
incubating with cells of 100 µM). Ten microliters from each well of the 10x drug plate
were added to corresponding columns on the cell plate. These plates were incubated for
24 and 72 hours. At the appropriate time point (after 24 and 72 hours), 20μL of 2 mg/mL
MTS and 5% phenazine methosulfate (PMS) was added to each well. The plates were
13

then incubated for 2-4 hours, and the absorbance at 490 nm was read with a Bio-Tek
spectrophotometer. Finally, calculations were performed to compute the percentage of
viable cells remaining; this was done by subtracting the number of drug blanks from the
number of cells, then dividing by the number of control cells and multiplying by 100.
The half maximal inhibitory concentration (IC50) was then determined by non-linear
regression using GraphPad Prism®.

RT-qPCR
To determine if the binding of the identified small molecules to the ADAM-15
promoter knocked out the transcription, real-time quantitative polymerase chain reaction
(RT-qPCR) was performed. In order to do this, the mRNA had to first be extracted from
the MCF-7 breast cancer cell line. For this protocol, 2 x 105 cells were plated per well in
1 mL of supplemented DMEM in a 12-well plate; these plates were incubated overnight.
The next day, variable amounts (25, 50, or 100 μM) of the identified small molecules, or
TMPyP4 (a known stabilizer of G-quadruplexes), were added to the cell plates. DMSO
and TMPyP4 were used as vehicle and positive controls, respectively. The plates were
incubated for 48 hours.
To extract the mRNA from the cell cultures, the GeneJET RNA Purification Kit
(Life Technologies) was used, following the "Mammalian Cultured Cells Total RNA
Purification" protocol. Briefly, the media was poured off of the cell plates, and the cells
were washed twice with PBS to remove residual medium. The cells were detached from
the plate and lysed by 350 μL of the Lysis Buffer supplemented with 1% β14

mercaptoethanol; the samples were then vortexed for 10 seconds to thoroughly
homogenize the mixture. Next, 360 μL of 100% ethanol was added to the samples,
which were mixed by pipetting. Up to 700 μL of the lysates was transferred to the
GeneJET RNA Purification Column, which was placed in a collection tube and
centrifuged at 12000 rpm for 1 minute. The flow-through was discarded, and the
purification column was placed in a new collection tube. Seven hundred microliters of
Wash Buffer 1, supplemented with ethanol, were added to the purification column, and
the column was then centrifuged at 12000 rpm for 1 minute. The flow-through was again
discarded. Next, 600 μL of Wash Buffer 2, supplemented with ethanol, was added to the
purification column, and the column was again centrifuged at 12000 rpm for 1 minute.
The flow-through was discarded, and an additional 250 μL of Wash Buffer 2 was added
to the purification column, which was centrifuged at 12000 rpm for 2 minutes. Flowthrough was discarded, and the purification column was placed in a sterile, RNase-free
microcentrifuge tube. Finally, 100 μL of nuclease-free water was added to the center of
the purification column membrane, and the tubes were centrifuged at 12000 rpm for 1
minute to elute the RNA. The concentrations of the eluted mRNA were measured using a
NanoDrop 2000 UV-Vis Spectrophotometer.
After the mRNA was extracted, it was used as a template to make complementary
DNA through reverse transcription. This was accomplished using the Maxima H Minus
First Strand cDNA Synthesis Kit, with dsDNase (Life Technologies). To eliminate the
genomic DNA, a mixture of 1 μL 10X dsDNase Buffer, 1 μL dsDNase, 500 ng of
template RNA, and variable amounts of nuclease-free water was placed on ice. This
mixture was then incubated for 2 minutes at 37°C, chilled on ice, centrifuged, and placed
15

again on ice. Next, 25 pmol of both oligo (dT)18 primer and a random hexamer primer
supplied with the kit were added to the tubes, along with 1 μL of 10 mM dNTP Mix and
variable amounts of nuclease-free water. The tubes were centrifuged, and 4 of μL 5X RT
Buffer and 1 μL Maxima H Minus Enzyme Mix was added. The samples were
centrifuged again, and incubated for 10 minutes at 25°C, followed by 22 minutes at 50°C.
The reaction was terminated by heating the samples at 85°C for 5 minutes.
The products from this reverse transcription reaction were then used for RTqPCR. A master mix of Taq buffer (SSoFast Mix, Bio-Rad), FAM-labeled ADAM-15
TaqMan primers (ABI), VIC-labeled GAPDH TaqMan primers (Bio-Rad), and water was
made. Sixteen microliters of the master mix was placed into each well on a PCR plate,
and 4 μL of the synthesized cDNA was then added in each well. The PCR plate was then
placed in a CFX Connect Real-Time PCR Detection System, and a two channel, two-step
fast amplification was run. Expression was calculated by normalizing the quantification
concentration (Cq) of ADAM-15 to the Cq of the control, GAPDH, using the equation
ΔCq S1 = CqFAM - CqVIC. Next, the sample effect was normalized to the control using
the equation ΔΔCq S1 = ΔCq S1 - ΔCq control. Finally, the fold change over expression was
calculated by 2-ΔΔCq (Haimes, 2010).
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RESULTS AND DISCUSSION
I. Compound Identification
FRET Melt
Because fluorescence resonance energy transfers are distance- and orientationdependent, they can give valuable information about the structure of nucleic acids (Ou,
2008). A fluorescence donor and acceptor were attached to opposite ends of the ADAM15 oligonucleotide. When screened with various small molecules, if the ligand stabilized
the G-quadruplex formed within the ADAM-15 promoter, the melting temperature
increased. Six hundred forty compounds were screened, and two distinct compounds
gave consistent increases in the melting temperature of ADAM-15, as shown in Table 1
and Figure 5.

Table 1. Shift in thermal stability of ADAM-15 oligonucleotide with compounds from NCI Plate
4728. Compounds in wells C5 and E7 increased the melting temperature.
A
B
C
D
E
F
G
H

1
0.33
-0.33
14.86
18.66

2
-2.96
0.08
-3.42
-3.76
-4.24
-3.9
-2.48
-2.51

3
-2.66
-0.51
-1.48
-4.03
-4.28
-4.98
-4.97
-2.49

4
-1.7
-3.98
-2.75
-2.37
1.73
-2.85
-3.22
-3.16

5
-1.26
-3.23
8.97
-4.41
-5.45
-4.19
-3.93
-4.26
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6
-4.21
-1.72
-4.3
-3.69
-3.99
-3.41
-2.52
-2.92

7
-5.03
-3.51
-3.94
-2.53
11.05
-3.28
-6.06
-3.93

8
-1.46
-2.93
-2.91
-5.45
-3.2
-1.2
-3
-1.97

9
-3.82
-2.08
-3.17
-4.96
-3.99
-4.78
-4.2
-1.41

10
-4.05
-2.52
-2.65
-5.86
-3.31
-4.71
-3.17
-2.57

11
-4
-4.49
-2.97
-2.52
-5.85
-3.08
-4.9
-2.28

NCI Plate 4728
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Figure 5. ADAM-15's shift in melting temperature when bound with ligands from NCI Plate
4728. Column 1, Rows C and D, contained KCl, a known potent G-quadruplex stabilizer, to
serve as a reference.

The two compounds that showed increased melting temperatures, C5 and E7 on NCI
plate 4728, correspond to NSC compounds 146771 and 260594, respectively. With
repeated screenings, NSC 146771 had an average increase in melting temperature of
11.88 ± 2.52 °C. NSC 260594 had an average increase in melting temperature of 11.97 ±
1.35 °C. These increases in melting temperature suggest the ability of the small
molecules to stabilize the G-quadruplex within the ADAM-15 promoter region.

Circular Dichroism
To confirm that these two ligands could stabilize the formation of a G-quadruplex
within the ADAM-15 promoter, electronic circular dichroism (CD) was used to
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determine asymmetrical structure formation – e.g. the G-quadruplex – and its thermal
stability. In general, non-chiral molecules such as the NSC compounds are CD-inactive;
however, DNA within the G-quadruplexes give characteristic spectral maxima and
minima, as shown in Figure 6. The negative minima of a G-quadruplex will be at about
240 nm; for a parallel G-quadruplex, the positive maxima will between 260 - 265 nm,
and for an anti-parallel G-quadruplex, there will be a positive maxima at about 290 nm.

Figure 6. Characteristic circular dichroism spectra for parallel and anti-parallel G-quadruplexes.
The spectra for "Chr 9 oligo 1" shows the characteristic peak and trough for a parallel Gquadruplex. The spectra for "Chr 18 oligo 17" shows the characteristic peaks and trough for a
mixed parallel (260 nm maxima) and an anti-parallel (290 nm maxima) G-quadruplex.
From Lam EY, Beraldi D, Tannahill D, Balasubramanian S. G-quadruplex structures are stable
and detectable in human genomic DNA. Nat Commun. 2013 April; 4(1796).
Figure
3: Motif and CD analyses substantiate G-quadruplex identification.

To verify that the NSC compounds 146771 and 260594 stabilized the G-quadruplexes,
the CD spectra for the ADAM-15 oligonucleotide were measured with and without the
NSC compounds. If the spectra with the compounds gave off similar signals as what are
characteristic for G-quadruplexes, then the hypothesis that these compounds stabilized
the G-quadruplex could be supported. The spectra, in units of molar ellipticity, for the
control, NSC compound 146771, and NSC compound 260594 are shown in Figure 7.
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Figure 7. Circular dichroism spectra for NSC compounds 146771 and 260594.

For NSC compound 146771, the negative minima was at 244 nm, and the positive
maxima was at 262 nm. For NSC compound 260594, the negative minima was at 242
nm, and the positive maxima was at 262 nm. Both of these spectra are indicative of
parallel G-quadruplex formation within the ADAM-15 promoter, supporting the
hypothesis that these compounds stabilize this predominant secondary DNA structure.
From the thermal circular dichroism experiment, the melting temperature (TM) of
the DNA, or the temperature at which half of the DNA is present as an intramolecular Gquadruplex, and half of the DNA is present in single-stranded form, was calculated. If
the melting temperature for the ADAM-15 oligonucleotide, in combination with one of
the NSC compounds, increased, it could be surmised that the compound improved the
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stability of the G-quadruplex, and thus improved the overall stability of the nucleic acid.
The results from the TM calculations are shown in Figure 8.

Figure 8. Melting temperatures (TM) of ADAM-15 oligonucleotide with NSC compounds
146771 and 260594.

As shown above, NSC compound 146771 did not notably affect the melting temperature
of the ADAM-15 oligonucleotide. However, NSC compound 260594 did increase the
ADAM-15 oligonucleotide's melting temperature by an average of 7.1 °C. Thus, it can
be concluded that NSC compound 260594 can bind to the G-quadruplex within the
ADAM-15 promoter and improve its stability.
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II. Compound Characterization
NSC 146771
The first compound to show affinity for the ADAM-15 G-quadruplex was NSC
146771, found in well C5 of NCI Plate 4728. This compound has a chemical formula of
C27H20N6O3, and its IUPAC name is 4-[(6-nitroquinolin-4-yl)amino]-N-[4-(pyridin-4ylamino)phenyl]benzamide (PubChem: CID 4532204). The 2D structure and 3D
conformer are shown in Figure 9 and Figure 10, respectively. NSC 146771 has a
molecular weight of 476.4861 g/mol, its logP value is 4.9, and it has 3 hydrogen-bond
donors and 7 hydrogen-bond acceptors (PubChem: CID 4532204). Therefore, according
to Lipinski's Rule of Five, this compound is predicted to be membrane permeable and
easily absorbed across the body (Leeson, 2012).

Figure 9. 2D structure of NSC compound 146771.
From PubChem Compound [Internet]. Bethesda (MD): National Library of Medicine (US),
National Center for Biotechnology Information. Compound Summary for: CID 4532204.
Available from:
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=51987431&viewopt=PubChem#itab
s-2d
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Figure 10. 3D conformation of NSC compound 146771.
From PubChem Compound [Internet]. Bethesda (MD): National Library of Medicine (US),
National Center for Biotechnology Information. Compound Summary for: CID 4532204.
Available from:
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=51987431&viewopt=PubChem#itab
s-2d

NSC 260594
The second compound to show affinity for the G-quadruplex within the ADAM15 promoter was NSC 260594, found in well E7 of NCI Plate 4728. This compound has
a chemical formula of C29H24N6O3, and its IUPAC name is 4-[(1-methyl-6-nitroquinolin4-ylidene)amino]-N-[4-[(1-methylpyridin-4-ylidene)amino]phenyl]benzamide
(PubChem: CID 319089). The 2D structure and 3D conformer of this compound are
shown in Figure 11 and Figure 12, respectively. NSC 260594 has a molecular weight of
504.53926 g/mol, its logP value is 4.4, and it has 1 hydrogen-bond donor and 7
hydrogen-bond acceptors (PubChem: CID 319089). Although its molecular weight is at
the upper end of the MW guidelines, this compound would still be predicted to easily
cross membranes and be absorbed according to Lipinski's Rule of Five.
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Figure 11. 2D structure of NSC compound 260594.
From PubChem Compound [Internet]. Bethesda (MD): National Library of Medicine (US),
National Center for Biotechnology Information. Compound Summary for: CID 319089.
Available from: http://pubchem.ncbi.nlm.nih.gov/compound/319089#section=Top

Figure 12. 3D conformation of NSC compound 260594.

From PubChem Compound [Internet]. Bethesda (MD): National Library of Medicine (US),
National Center for Biotechnology Information. Compound Summary for: CID 319089.
Available from: http://pubchem.ncbi.nlm.nih.gov/compound/319089#section=Top
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III. Mechanistic Confirmation
Cytotoxicity MTS Assay
An MTS assay was done to investigate if the NSC compounds 146771 and 260594 had
any cytotoxic effects on breast cancer cells. If the compounds were cytotoxic to the cells,
they could cause apoptosis or necrosis, leading to loss of membrane integrity and release
of the cells' contents. The MTS assay measures the cells' ability to reduce 3-(4,5dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium
(MTS), in the presence of phenazine methosulfate (PMS), to a colored formazan product.
Viable, or alive, cells are able to reduce the tetrazolium salt in their mitochondria,
whereas non-viable cells cannot form the formazan product. The results of this assay
showed that these two compounds did not cause cytotoxicity within the MCF-7 breast
cancer cell line (Figure 13). As ADAM-15 is a zymogen involved in metastasis and
invasion, but not cell growth and proliferation, this result was anticipated if the ADAM15 promoter G-quadruplex is the primary structure being stabilized by these compounds.
The lack of cytotoxicity may also indicate that they were not modulating any genes at all;
thus, the effects of the NSC compounds on gene expression need to be evaluated by
measuring changes in mRNA.
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Figure 13. MCF-7 cell viability after MTS assay done with NSC compounds 146771 and
260594.

RT-qPCR
To validate the hypothesis that small molecule stabilization of G-quadruplexes
within the ADAM-15 promoter could reduce transcription, quantitative polymerase chain
reaction (qPCR) was performed. A TaqMan® probe-based assay was employed, which
allowed for specific hybridization between the primer-probe pair and the gene target.
Two particular primer-probe pairs were used: a FAM-labeled ADAM-15 probe-primer
pair, to measure the gene of interest, and a VIC-labeled GAPDH probe-primer pair, to
measure the housekeeping gene and normalization control. When the probes are intact,
the quencher dye on the 3'-end greatly reduces the fluorescence emitted by the reporter
dye on the 5'-end because of their close proximity. However, as cDNA of the target
sequence is amplified, the annealed probe is displaced by extension from elongation of an
upstream primer, and is cleaved by the 5' nuclease activity of Taq DNA polymerase.
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This cleavage separates the reporter dye from the quencher dye; therefore, the emission
from the reporter dye is increased. Additionally, since the probe has been removed from
the target strand, the primer can continue to extend to the end of the template strand.
With each cycle, additional reporter dyes are cleaved from their respective probes, which
results in an increase in fluorescence intensity proportional to the amount of mRNA that
is amplified (Life Technologies, 2015). Figure 14 shows the amplification of VIClabeled GAPDH in green and of FAM-labeled ADAM-15 in blue. GAPDH served as a
control because of its low variability within a tissue; as expected, this amplified during
the polymerase chain reaction. ADAM-15 was also amplified from untreated and
vehicle-controlled wells; when NSC compounds 146771 and 260594 were added,
ADAM-15's amplification curve showed dose-dependent message knockdown, as
evidenced by a right-hand shift in the fluorescence detection curves. The higher Cq
values attained when the NSC compounds were added corresponded to lower expression;
therefore, these compounds showed effectiveness in silencing the ADAM-15 transcript.
To assess the NSC compounds' ability to silence the ADAM-15 gene, relative
gene expressions were calculated with the ΔΔCq method, using GAPDH as a reference
gene, and normalizing to vehicle control treated cells (Figure 15). One hundred
micromolars of TMPyP4 (a known G-quadruplex stabilizer) significantly decreased
expression of ADAM-15 by over 99%. Twenty-five micromolars of NSC compound
146771 trended toward decreased expression of ADAM-15, but did not reach statistical
significance (p=0.06). However, 25 μM of NSC compound 260594 completely knocked
out the expression of ADAM-15, relative to control. Together, these data support that
two compounds identified ex vivo show potential to regulate the ADAM-15 promoter G27

quadruplex in vitro and to silence transcription. In particular, the more stabilizing
compound NSC 260594 significantly decreased ADAM-15 expression. This compound
warrants further testing in a dose-dependent manner, and more pre-clinical testing in an
expanded cell line panel and in vivo.

Figure 14. Amplification of GAPDH (control) and ADAM-15. VIC-labeled GAPDH
amplification is indicated in green, and FAM-labeled ADAM-15 amplification is indicated in
blue.
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Figure 15. Expressivity of ADAM-15 mRNA in MCF-7 cells after treatment with NSC
compounds 146771 and 260594.
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CONCLUSION
Metastatic breast cancer is a very serious disease that affects an estimated 162,000
women in the United States per year (MBCN, 2015). While the survival rates for many
cancers have improved in recent years, the 5-year relative survival rate for metastatic
(Stage IV) breast cancer remains at only 22% (American Cancer Society, 2014). Because
metastatic breast cancer can be so deadly, there is a great need for improved therapeutic
options. A novel approach is the targeting of ADAM-15, a protein whose expression is
up-regulated in the more aggressive and invasive breast cancer phenotypes. The critical
promoter region of ADAM-15 contains a guanine-rich sequence that is capable of
forming alternate DNA structures known as G-quadruplexes; the stabilization of these Gquadruplexes has the potential to reduce transcription of this over-expressed ADAM-15
protein (Brown, 2013). In the current study, 640 compounds were screened for their
ability to stabilize ADAM-15 promoter's G-quadruplexes. Two compounds, NSC
146771 and NSC 260594, demonstrated putative ability to stabilize the G-quadruplexes
by causing an increase in the melting temperature. These compounds did not cause
cytotoxicity, and NSC 260594 was able to knock out the transcription of ADAM-15.
Future areas of study include conducting cell migration and invasion assays to assess if
these compounds, particularly NSC 260594, are capable of preventing metastasis of
breast cancer cells. Other future areas of research include assessing the ability of these
small molecules to be optimized through analog development, preclinical testing, and
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clinical testing into FDA approved drugs. In particular, their selectivity for the ADAM15 promoter G-quadruplex, their cancer-versus-normal specificity, and their
pharmacokinetic properties such their absorption, distribution, metabolism, and excretion
(ADME) need to be enhanced.
Overall, G-quadruplex stabilizers have the potential to revolutionize the treatment
of many cancers. G-quadruplexes can be found in telomeres and various oncogene
promoters; when these structures are stabilized, transcription is decreased and cancer
progression putatively stops. One of ADAM-15's most significant activities is the
cleavage of E-cadherin; this cleavage disrupts cell-cell contact and considerably
contributes to metastasis. Additionally, the solubilized E-cadherin fragment stabilizes the
heterodimerization of HER2 and HER3, leading to increased intracellular signaling and
further contributing to metastasis and proliferation. Furthermore, ADAM-15's overexpression in breast cancer is coincidental with the up-regulation of HER2; thus, these
small molecules targeted towards ADAM-15 promoter's G-quadruplexes have the
potential to be used in combination with HER2-targeted drugs such as Trastuzumab to
improve its efficacy and increase the duration and quality of life in thousands of breast
cancer patients a year.
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